Does surgery benefit patients with oligometastatic or metastatic prostate cancer? – A retrospective cohort study and meta‐analysis

Si, Shubin; Zheng, Bin; Wang, Zhenlin; Niu, Zhihong

doi:10.1002/pros.24170

Cited by 14 publications

(22 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In total, 10 relevant studies [25][26][27][28][29][30][31][32][33][34] incorporating 888 patients were included in the present analysis after having met with study selection criteria (Table 1). All included prospective studies were considered to be of high quality (Table 2).…”

Section: Resultsmentioning

confidence: 99%

“…2019 [ 33 ] 49 ST 23 22.8(14-43) 65.2%(3-y) 65.2%(3-y) CRP 26 19.2(9-42) 76.9%(3-y) 76.9%(3-y) Shubin Si al. 2021 [ 34 ] 84 RP 27 76.67 ± 9.66 96.2%(3-y) 76.0%(5-y) -RP 57 76.42 ± 9.69 94.7%(3-y) 74.9%(5-y) Continuous variables were expressed as (mean±SD), mean (range) or median (IQR) PSA The nadir of prostate-specific antigen, CSS Cancer-specific survival, OS overall surviva, RP radical retropubic prostatectomy, CRP cytoreductive prostatectomy, RARP robot-assisted radical prostatectomy, ADT androgen deprivation therapy …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases: a systematic meta-analysis

Mao

Yang³

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

Background Whether cytoreductive prostatectomy (CRP) should be performed in patients with oligometastatic prostate cancer (OPC) remains controversial. The goal of this systematic meta-analysis was to assess the efficacy of CRP as a treatment for OPC. Methods This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement. Data sources included publications in the PubMed, Embase, the Cochrane Library, EBSCO, and Web of Science (SCI) databases as of May 2022. Eligible articles included prospective studies comparing the efficacy of CRP to a lack of CRP in patients with OPC. Results In total, 10 publications incorporating 888 patients were analyzed. Tumor-reducing prostatectomy was found to have no significant effect on long-term or short-term OS [OR = 2.26, 95% CI (0.97, 5.28), P = 0.06] and [OR = 1.73, 95% CI (0.83, 3.58), P = 0.14], but it significantly improved patient long-term or short-term CSS [OR = 1.77, 95% CI (1.01, 310), P = 0.04] and [OR = 2.71, 95% CI (1.72, 4.29), P < 0.0001] and PFS [OR = 1.93, 95% CI (1.25, 2.97), P = 0.003]. Conclusion These results suggest that cytoreductive prostatectomy can confer survival benefits to OPC patients. Trial registration INPLASY protocol 202260017 https://doi.org/10.37766/inplasy2022.6.0017.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases: a systematic meta-analysis

Mao

Yang³

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…3 B). Three studies assessed the OS of oligometastatic PCa, [ 7 , 12 , 13 ] and pooled data showed cytoreductive surgery did not significantly affect the OS (OR = 1.33, 95% CI 0.87–2.02, P = .19, Fig. 4 ).…”

Section: Resultsmentioning

confidence: 99%

Cytoreductive radical prostatectomy or radiation therapy for metastases prostate cancer: Evidence from meta-analysis

Peng¹,

Huang

2022

Medicine

View full text Add to dashboard Cite

Background: Cytoreductive radical prostatectomy (RP), transurethral resection of the prostate, and radiation therapy were the main local treatments for oligometastatic prostate cancer (PCa). An optimal local treatment for metastases PCa was not consensus. The purpose of this study was to evaluate the effect on these local treatments for patients with metastases PCa.Methods: All relevant studies were systematically searched through PubMed, Web of Science through November 1, 2021. Studies were screened by inclusion and exclusion criteria. Progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) were evaluated by this meta-analysis.Results: Eleven studies were identified that met the inclusion criteria. 644 patients received cytoreductive surgery, 8556 patients received no surgery or radiation therapy (RT), and 461 patients received RP + androgen deprivation therapy compared with 746 patients who received RT. Pooled data indicated that cytoreductive surgery significantly prolonged the PFS (OR = 0.65, 95% CI 0.53-0.80, P < .0001), CSS and OS (OR = 0.49, 95% CI 0.43-0.56, P < .00001; and OR = 0.80, 95% CI 0.72-0.88, P < .00001; respectively). Comparing cytoreductive surgery with RT, CSS, and OS were similar (OR = 0.82, 95% CI 0.67-1.01, P = .06; and OR = 0.93, 95% CI 0.79-1.09, P = .39; respectively).Conclusions: Cytoreductive radical prostatectomy significantly prolonged the PFS for metastatic PCa. Although OS was considered a-not-so significant difference between cytoreductive surgery and non-local therapy, non-local treatment was not recommended.Abbreviations: ADT = androgen deprivation therapy, CSS = cancer-specific survival, mHSPC = metastatic hormone-sensitive prostate cancer, OR = odds ratio, OS = overall survival, PCa = prostate cancer, PFS = progression-free survival, RP = radical prostatectomy, SEER = Surveillance Epidemiology and End Results, TURP = transurethral resection of the prostate.

show abstract

“…A meta-analysis and retrospective cohort study [34] compared survival outcomes in the RP+ ADT vs ADTonly group of patients with OMPCa. The results suggest that the addition of surgery does not increase CRPC-free survival.…”

Section: P R E P R I N Tmentioning

confidence: 99%

Oligometastatic Disease in Prostate Cancer. Evolving paradigm: current knowledge, diagnostic techniques and treatment strategies

Matuszczak

Salagierski

2022

Arch Med Sci

View full text Add to dashboard Cite

Although the oligometastatic type of prostate cancer (PCa) is the subject of much research, it still has no clear biological and clinical specification. It is a condition between localized and extensive PCa, in which early diagnosis and treatment are favorable prognostic factors. Not so long ago, just the presence of metastases was considered a poor prognosis with limited therapeutic options. Such patients were treated as if they had advanced cancer and received hormonal treatment. However, clinical trials have shown that Androgen Deprivation Therapy (ADT) can be delayed in patients with an oligometastatic PCa (OMPCa). New therapeutic methods are being developed thanks to the advanced research and various concepts to understand the underlying biology of this type of cancer. In this review, the intention is to bring together the latest information in this domain.

show abstract

Does surgery benefit patients with oligometastatic or metastatic prostate cancer? – A retrospective cohort study and meta‐analysis

Abstract: Background: To evaluate long-term oncological outcomes of radical prostatectomy (RP) plus androgen deprivation therapy (ADT) in oligometastatic prostate cancer (PCa) patients.Methods: Our study included oligometastatic PCa patients hospitalized between

Cited by 14 publications

References 39 publications

Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases: a systematic meta-analysis

Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases: a systematic meta-analysis

Cytoreductive radical prostatectomy or radiation therapy for metastases prostate cancer: Evidence from meta-analysis

Oligometastatic Disease in Prostate Cancer. Evolving paradigm: current knowledge, diagnostic techniques and treatment strategies

Contact Info

Product

Resources

About